AbbVie Inc. buy Evercore ISI
Start price
28.04.25
/
50%
€166.20
Target price
28.04.26
€180.54
Performance (%)
-3.85%
Price
04.07.25
€159.80
Summary
This prediction is currently active. With a performance of -3.85%, the BUY prediction for AbbVie Inc. by Evercore_ISI is down slightly. This prediction currently runs until 28.04.26. The prediction end date can be changed by Evercore_ISI at any time. Evercore_ISI has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| AbbVie Inc. | 0.752% | 0.752% |
| iShares Core DAX® | 0.763% | -0.955% |
| iShares Nasdaq 100 | 1.401% | 2.163% |
| iShares Nikkei 225® | -0.085% | 2.249% |
| iShares S&P 500 | 1.683% | 1.702% |
Comments by Evercore_ISI for this prediction
In the thread AbbVie Inc. diskutieren
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Evercore ISI from $204.00 to $205.00. They now have an "outperform" rating on the stock.
Ratings data for ABBV provided by MarketBeat